vimarsana.com
Home
Live Updates
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program : vimarsana.com
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
Arcturus to present new Phase 1b interim data for ARCT-032 at European Cystic Fibrosis Conference on June 7, 2024
First four CF patients demonstrated an average improvement of 4% FEV1 after two...
Related Keywords
United Kingdom ,
China ,
Japan ,
California ,
United States ,
San Diego ,
Scotland ,
Joseph Payne ,
Juergen Froehlich ,
Linkedin ,
Nasdaq ,
Drug Administration ,
Mrna Technology ,
Arcturus Therapeutics Holdings Inc ,
Twitter ,
European Medicines Agency ,
Arcturus Therapeutics Holdings ,
European Cystic Fibrosis Conference ,
Forced Expiratory Volume ,
Chief Medical Officer ,
Orphan Medicinal Product Designation ,
Orphan Drug Designation ,
Private Securities Litigation Reform Act ,
Annual Report ,
vimarsana.com © 2020. All Rights Reserved.